Levofloxacin Ophthalmic Solution Recalled Due to Manufacturing Practice Deviations
Akorn, Inc. is recalling all lots of Levofloxacin Ophthalmic Solution 0.5% due to manufacturing practice deviations. The firm went out of business and could not continue required stability studies.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall involving manufacturing practice deviations. The source does not report any illnesses, injuries, or hospitalizations. Per the rubric, FDA Class II without reported harm is scored as High (3), as the hazard is theoretical rather than confirmed.
Plain-English summary
Akorn, Inc. is recalling all lots of Levofloxacin Ophthalmic Solution, 0.5% in 5 mL bottles (Rx only). The product is distributed nationwide in the United States and Puerto Rico.
The recall is due to Current Good Manufacturing Practice (CGMP) deviations. The manufacturer went out of business and was unable to continue the stability studies required to ensure product quality and effectiveness over its shelf life.
The recalled product
- Product
- Levofloxacin Ophthalmic Solution, 0.5%, 5 mL bottles, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic antibiotic
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 86 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · cgmp deviation
See all →- ModerateABC Compounding Recalls PRO CHEM BAN AID Antiseptic Hand Soap
FDA (Drugs) · 2026-11-04
- ModerateLynx Antibacterial Hand Soap Recalled for CGMP Deviations
FDA (Drugs) · 2026-11-04
- ModerateABC Compounding Recalls Antiseptic Hand Soap Due to Manufacturing Deviations
FDA (Drugs) · 2026-11-04
- ModerateABC Compounding Recalls Chemseptic Due to Manufacturing Deviations
FDA (Drugs) · 2026-11-04
- ModerateABC Compounding Recalls Aerocare Sani Mango Antiseptic Hand and Body Wash
FDA (Drugs) · 2026-11-04
Similar recalls
- ModerateAkorn recalls Levofloxacin eye drops due to manufacturing compliance issues
FDA (Drugs) · 2023-01-25
- ModerateCiprofloxacin ophthalmic solution recalled for manufacturing practice deviations
FDA (Drugs) · 2023-01-25
- ModerateOfloxacin Ophthalmic Solution Recalled Nationwide for Manufacturing Quality Issues
FDA (Drugs) · 2023-01-25
- ModerateAkorn Recalls Moxifloxacin Ophthalmic Solution for CGMP Deviations
FDA (Drugs) · 2023-01-25
- HighBetaxolol ophthalmic solution recalled for manufacturing process violations
FDA (Drugs) · 2023-01-25
- HighKetorolac Tromethamine ophthalmic solution recalled due to manufacturing deviations
FDA (Drugs) · 2023-01-25